Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlloStim for viral protection in healthy elderly adults
NCT04441047Phase 2Completed
- Sponsor
- Mirror Biologics, Inc.
- Start
- Jul 2021
- Primary completion
- Mar 2023
- Modality
- Native Immune Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allostim in respiratory viral infection, sponsored by Mirror Biologics, Inc. Primary endpoints: Frequency of vaccine events, Proportion of subjects with positive T-cell response and 1 more. Started Jul 2021; status: completed.
02
Drugs
allostim
03
Conditions
respiratory viral infection
Beyond the preview
Go deeper on NCT04441047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04441047.